#United States #New York #Gross Law Firm #Regeneron Pharmaceuticals #class action litigation

Important Notice for Regeneron Pharmaceuticals Shareholders

In a significant development for investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), the Gross Law Firm has issued a crucial reminder regarding the upcoming deadline for shareholders to register as lead plaintiffs in a class action lawsuit. The deadline is set for September 14, 2026, which means time is running out for affected investors to take action.

The Issue at Hand

The lawsuit concerns allegations that Regeneron misled its investors while promoting its Phase III Fianlimab-Libtayo Study, presenting overly optimistic statements about clinical trial results that ultimately proved to be unfounded. Shareholders who purchased stock of Regeneron between August 1, 2025, and May 15, 2026, are particularly urged to consider their rights in this matter.

The complaint claims that Regeneron's management concealed critical flaws in the study's statistical assumptions, misrepresenting the effectiveness of the treatment being tested. Notably, the company is accused of failing to inform investors about the study's inability to achieve significant results, which led to a substantial decline in stock value shortly after negative announcements about the trial's outcome were made public.

Significant Stock Price Declines

Regeneron's stock faced a sharp decline following these disclosers. For instance, on April 28, 2026, the shares closed at $731.77, but after revealing issues related to the trial during an earnings call, the price dropped to $686.36 the very next day—an alarming decrease of approximately 6.2%. This downward trend continued on May 15, 2026, when further negative announcements regarding the Phase 3 trial caused the stock price to tumble again, closing at $629.68, down nearly 10% from the previous closing.

Next Steps for Shareholders

For shareholders who purchased shares of Regeneron during the specified timeframe, registering as a lead plaintiff involves no cost or obligation. By signing up, investors are eligible to monitor the progress of the case, ensuring that they receive all relevant updates. This process allows shareholders to remain informed about potential recoveries as the case unfolds.

Interested shareholders can find the registration link and submit their information through the following site: Regeneron Pharmaceuticals Loss Submission Form.

Why Choose Gross Law Firm?

The Gross Law Firm has built a reputation as a reputable national class action law firm focused on protecting investor rights. The firm is committed to advocating for those impacted by corporate misconduct, fraud, and unethical business practices. Investors who have suffered from misleading representations can count on the Gross Law Firm to strive for acknowledgment and restoration of their losses.

As a shareholder of Regeneron Pharmaceuticals, this is your opportunity to act and defend your rights as an investor. Don't wait too long; remember that the deadline of September 14, 2026, is fast approaching. Start the registration process today to ensure that you are not left out of potential recovery in this ongoing legal matter.

For any inquiries, shareholders may contact the Gross Law Firm at their New York office:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Phone: (646) 453-8903
Email: [email protected]

Stay informed and safeguard your investments!